CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 563 enrolled
Drug / intervention
Capecitabinedrug
Likely dose
Capecitabine 1250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01664494
NCT01664494N/ACompleted
CompareCT.gov

A Non-Interventional Trial of Xeloda in Metastatic Colorectal Cancer, Adjuvant Colon Cancer, Advanced Gastric Cancer and Breast Cancer

Hoffmann-La Roche·observational·Posted Aug 14, 2012·Updated May 2, 2016

In Brief

An observational study evaluating Capecitabine for Breast Cancer, Colorectal Cancer, Gastric Cancer. Completed, enrolled 563 participants across 1 site.

Detailed Summary

This multi-center observational study will evaluate the use of Xeloda (capecitabine) in patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer and breast cancer in routine clinical practice. Eligible patients receiving treatment with Xeloda according to product label will be followed for up to 10 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Colorectal Cancer, Gastric Cancer
CountriesAustria
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 14, 2012
Enrollment StartApr 1, 2010
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.9 years ago

Interventions

Capecitabinedrug

Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.